About Inbiopro
Inbiopro is a Healthcare company based in Bengaluru (India) founded in 2007, and was acquired by Strides Arcolab in December 2010. Biosimilars and biological therapeutics are developed in India. Inbiopro has raised $31.7 million across 6 funding rounds from investors including Accel, Strides Arcolab and Tenshi Life Sciences. The company has 1,124 employees. Inbiopro was last valued at $57.1 million in May 2017. Its focus areas include Diversified Pharmaceuticals. Its legal entity in India is Stelis Biopharma Private Limited (U24100KA2012PTC063995).
Company details
Inbiopro Solutions, a biopharmaceutical company, develops and manufactures biologicals in India. It offers biosimilars; and therapeutics in the areas of oncology, rheumatoid arthritis, cardio vascular diseases, and others. The company also provides molecular biology outsourcing solutions, including de novo gene synthesis, gene cloning, DNA construct, plasmid preparation, and site directed mutagenesis. In addition, it provides tools for the creation and characterization of stable cell lines expressing a gene of interest; transient transfection; assay development and screening; analytical servicesprotein characterization; and purity analysis services. Its biologics are made accessible through a network of licensing partnerships.
- Headquarters Bengaluru, India
- Employees 1,124
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website inbiopro.com
- Social LinkedIn
- Acquired by Strides Arcolab (Dec 2010)
- Legal Name Stelis Biopharma Private Limited
- Date of Incorporation 16 May, 2012
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue$3.02 M (USD)875as on Mar 31, 2021
- Net Profit-$16.28 M (USD)14as on Mar 31, 2021
- EBITDA-$9.48 M (USD)15as on Mar 31, 2021
- Total Equity Funding$31.7M (USD)
in 6 rounds
- Latest Funding Round$11.26M (USD), Series A
May 2017
- InvestorsAccel
& 9 more
- Employee Count1,124
- Acquired byStrides Arcolab
(Dec 2010)
Associated legal entities of Inbiopro
Inbiopro operates through Stelis Biopharma Private Limited (amalgamated). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Stelis Biopharma Private Limited CIN U24100KA2012PTC063995 | Amalgamated | 16 May 2012 | Bangalore, Karnataka | 2 | View details |
Funding Insights of Inbiopro
Inbiopro has successfully raised a total of $31.7M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $11.26 million completed in May 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $31.7M
- Total Rounds 6
- Last Round Series A — $11.26M
- First Round $581,175
(Dec 2007)
- Investors Count 10
All 6 funding rounds of Inbiopro with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2017 | $11.26M | Series A | $57.1M | Tenshi Life Sciences | |
| Feb 2016 | $19.02M | Series A | $42.49M | gmspharmaceuticals | |
| Jul 2010 | $123,393 | Angel Round | $••••• | B K Iyer | |
| Jun 2009 | $515,465 | Seed | $••••• | Accel | – |
| Dec 2008 | $195,676 | Seed | $••••• | Accel | – |
| Dec 2007 | $581,175 | Seed | $••••• | Accel |
| Date | Valuation | Stage |
|---|---|---|
| May 2017 | $57.1M | •••••••• |
| Feb 2016 | $42.49M | •••••••• |
| Jul 2010 | $••••• | •••••••• |
| Jun 2009 | $••••• | •••••••• |
| Dec 2008 | $••••• | •••••••• |
| Dec 2007 | $••••• | •••••••• |
Full valuation and stage history of Inbiopro
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $57.1M (May 2017). 10 investors in total: 4 institutional and 6 angel.
Investors in Inbiopro
Inbiopro has secured backing from 10 investors, including institutional, angel, and venture fund investors. Prominent investors backing the company include Accel, Strides Arcolab and Tenshi Life Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Accel is recognized as a leading venture capital firm. | 1983 | accel.com | Palo Alto, United States | |
Delivers advanced finished dosage pharmaceuticals using global infrastructure and quality systems. | 2007 | tenshi.co.in | Bengaluru, India | |
Manufacturer of IP-led niche finished dosage formulations and soft gelatin capsules | 1990 | stridesarco.com | Bengaluru, India | |
Provides research, development, and manufacturing of pharmaceutical drugs. | gmspharmaceuticals.com | China | ||
BK B K Iyer | unknown_8323b138ff3a41a7b | |||
TJ Tanya Julka | unknown_dc05dbb2db0c414fb | |||
SE Sunil Edwards | unknown_5363e4106bdd4353a | |||
MV Manohar Varun Raj | unknown_163054e142934c238 | |||
MG Menaka Gubbi | unknown_b5f39106211a46c2a | |||
PT Pradeep Tharakan | unknown_dd271a1aa23648e7a |
Investor details for Inbiopro
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Stelis Biopharma Private Limited (Inbiopro)
Stelis Biopharma Private Limited is the primary company behind Inbiopro. The board of Stelis Biopharma Private Limited currently have 2 directors; the longest-serving is Sudhir Krishna Kanchan, appointed in 2012. 1 earlier director has ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sudhir Krishna Kanchan DIN 01606191 | Director | 16 May 2012 | 14 yrs 5 mo | Stelis Biopharma Private Limited |
| Joe Thomas Mangalam DIN 00468077 | Additional Director | 06 Mar 2014 | 12 yrs 7 mo | Stelis Biopharma Private Limited |
Timeline of Inbiopro
5 dated milestones of Inbiopro across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Inbiopro is founded.
- Funding First funding round of $581K.
- Milestone Reaches Minicorn status.
- Exit Acquired by Strides Arcolab.
- Funding Latest funding round, Series A, of $11.3M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Inbiopro
Complete news archive for Inbiopro
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inbiopro
Inbiopro was founded in 2007.
Inbiopro is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Inbiopro is a funded company, having raised a total of $31.7M across 6 funding rounds to date. The company's 1st funding round was a Seed of $581.18K, raised on Dec 2007.
Inbiopro has 1,124 employees.
Annual revenue of Inbiopro is $3.02M as on Mar 31, 2021.
Inbiopro Solutions, a biopharmaceutical company, develops and manufactures biologicals in India. It offers biosimilars; and therapeutics in the areas of oncology, rheumatoid arthritis, cardio vascular diseases, and others. The company also provides molecular biology outsourcing solutions, including de novo gene synthesis, gene cloning, DNA construct, plasmid preparation, and site directed mutagenesis. In addition, it provides tools for the creation and characterization of stable cell lines expressing a gene of interest; transient transfection; assay development and screening; analytical servicesprotein characterization; and purity analysis services. Its biologics are made accessible through a network of licensing partnerships.
Inbiopro has 10 investors. Key investors include Accel, Strides Arcolab, Tenshi Life Sciences, gmspharmaceuticals, and B K Iyer.
The valuation of Inbiopro is $57.1M as of May 2017.
Inbiopro operates through Stelis Biopharma Private Limited.
Yes. Inbiopro was acquired by Strides Arcolab in December 2010.
The legal entities of Inbiopro currently have 2 directors, including Joe Thomas Mangalam, Sudhir Krishna Kanchan.